目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T75516 | |||
Seconeolitsine,一种抗生素,是一种靶向拓扑异构酶 I(TopA)的抑制剂。Seconeolitsine 也是一种新的抗菌剂,可以抑制 S. pneumoniae 的生长。Seconeolitsine 具有抑制 TopA 的活性,其 b>IC50值为 17 μM。Seconeolitsine 可用于对其他抗生素耐药的肺炎链球菌感染的研究。 | |||
T37844 | |||
Kigamicins are natural antitumor antibiotics that selectively kill pancreatic cancer PANC-1 cells only under nutrient-starved conditions. They also show antimicrobial activity against Gram-positive bacteria, including methicillin-resistant S. aureus. Kigamicin C inhibits PANC-1 cell survival in nutrient-deprived media at a 100-fold lower concentration than that required for cells maintained in nutrient-rich media. A related compound, kigamicin D, is active in vivo, suppressing the tumor growth of several pancreatic cancer cell lines in nude mice. It blocks the activation of Akt induced in PANC-1 cells placed in nutrient-deprived media. Kigamicin can also induce necrosis in human myeloma cells, but not normal lymphocytes, maintained in nutrient-rich media (CC50 = 100 nM). | |||
T74917 | |||
KPC-2-IN-1,硼酸衍生物,是一种有效的 KPC-2抑制剂,其 Ki 值为 0.032 μM。KPC-2-IN-1 能增强 cefotaxime 在表达 KPC-2的大肠杆菌中的活性。KPC-2-IN-1 对人类 HEK-293 细胞显示良好的耐受性,可用于大肠杆菌耐β-lactam 类抗生素的研究。 | |||
T75994 | |||
SPR741 TFA (NAB741 TFA),一种源自多粘菌素B的阳离子肽增效剂,通过提升革兰氏阴性细菌外膜通透性用于对抗重度革兰氏阴性细菌感染。它能够抑制多重耐药性革兰氏阴性细菌,并在与抗生素联用时扩大抗生素的活性谱。 | |||
T80385 | |||
K11是一种具有针对MDR/XDR K. pneumoniae活性的抗菌肽(MIC: 8-512 μg/mL),能够抑制该细菌的生物膜的形成。它还可以与多种抗生素(如Chloramphenicol、Meropenem、Rifampicin等)产生协同效应,增强对耐药K. pneumoniae的抗性。此外,K11显示出良好的高温稳定性和在宽pH范围内的稳定性。 | |||
T36049 | |||
Linearmycin B is a polyene antibiotic that has been found inStreptomyces.1It induces lysis and degradation ofB. subtilisas a component ofStreptomycesMg1 extract.2 1.Sakuda, S., Guce-Bigol, U., Itoh, M., et al.Novel linear polyene antibiotics: LinearmycinsJ. Chem. Soc., Perkin Trans. 1182315-2319(1996) 2.Stubbendieck, R.M., and Straight, P.D.Escape from lethal bacterial competition through coupled activation of antibiotic resistance and a mobilized subpopulationPLoS Genet.11(12)e1005722(2015) | |||
T76973 | |||
Tosatoxumab (AR-301; KBSA301) 为一种人源化免疫球蛋白G1类单克隆抗体,专一性地中和金黄色葡萄球菌α毒素(α-溶血素; Hla),通过与该毒素N末端表位结合,防止其功能性毒素孔的寡聚化。此抗体对于金黄色葡萄球菌引起的肺炎,作为传统抗生素疗法的辅助,展现出被动免疫治疗的潜力。 | |||
T37723 | |||
IT-143A is a bacterial metabolite originally isolated fromStreptomycessp. IT-143.1It is active against the bacteriumM. luteus(MIC = 6.25 μg/ml) and the fungiA. fumigatusandT. rubrumin vitro(MICs = 12.5-25 μg/ml). 1.Urakawa, A., Sasaki, T., Yoshida, K., et al.IT-143-A and B, novel piericidin-group antibiotics produced by Streptomyces SpJ. Antibiot. (Tokyo)49(10)1052-1055(1996) | |||
TMIH-0530 | |||
Sulbactam-d2 是 Sulbactam 的氘代化合物。Sulbactam 的 CAS 号为 68373-14-8。Sulbactam是一种竞争性、不可逆的 β-内酰胺酶抑制剂,抑制耐多药不动杆菌-鲍曼不动杆菌复合物。它具有抗菌活性。 | |||
T38021 | |||
Obafluorin is a β-lactone antibiotic that has been found in P. fluorescens.1 It is active against S. aureus, S. faecalis, K. pneumoniae, and P. vulgaris (MIC = 125 μg/ml for all). |1. Pu, Y., Lowe, C., Sailer, M., et al. Synthesis, stability, and antimicrobial activity of (+)-obafluorin and related β-lactone antibiotics. J. Org. Chem. 59(13), 3642-3655 (1994). |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02373 | Metallo-beta-lactamase type 2 Protein, Klebsiella pneumoniae, Recombinant (His) | Klebsiella pneumoniae | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Does not confer resistance to the polymixin colistin or the fluoroquinolone ciprofloxacin.
|
|||||
TMPH-03488 | Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) | Serratia marcescens | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 32.6 kDa and the accession number is P52699.
|
|||||
TMPH-00587 | Beta-lactamase TEM Protein, E. coli, Recombinant (His & SUMO) | E. coli | E. coli | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPH-00586 | Beta-lactamase TEM Protein, E. coli, Recombinant (His) | E. coli | P. pastoris (Yeast) | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPY-01812 | Enoyl-ACP Reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Enoyl-ACP reductase, also known as NADH-dependent enoyl-ACP reductase and FABI, is a cell inner membrane and peripheral membrane protein which belongs to theshort-chain dehydrogenases/reductases (SDR) family and FabI subfamily. Microorganisms produce many kinds of antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FABI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. The antibiotic diazaborine interferes with the activity by binding to the protein. FABI is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds.
|